OptiNose — Q1 2022 Earnings Presentation
14 slides from OptiNose's earnings presentation, May 12, 2022
Slide 1: Building a Leading ENT / Allergy Specialty Company Corporate Presentation
Building a Leading ENT / Allergy Specialty Company Co r p o r a t e P r e s e n t a t i o n May 1 2 , 2 0 2 2
Slide 2: Forward-Looking Statements
2 Forward‐Looking Statements This presentation and our accompanying remarks contain “forward‐looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward‐looking statements for this
Slide 3: Q1 2022 Performance
Q1 2022 Performance
Slide 4: Key Takeaways and Q1 2022 Highlights
4 Key Takeaways and Q1 2022 Highlights Achieved Y/Y XHANCE Net Revenue Growth of 35% in Q1 2022 FY 2022 Revenue Guidance Implies Y/Y Growth of at least 22% Positive Top‐Line Results from ReOpen1 Reported in Q1 2022 +35% XHANCE Net Revenue Growth Q1 2022/Q1 2021 +21% XHANCE Net Revenue per TRx Growth
Slide 5: XHANCE New and Total Prescriptions
5 XHANCE New and Total Prescriptions XHANCE New Prescriptions increased 9% and Total Prescriptions increased 11% from Q1 2021 to Q1 2022 Estimated based on monthly prescription data from third parties and XHANCE preferred pharmacy network. The Market on this slide is defined as the sum of all intran
Slide 6: XHANCE Market Share & Prescribers by Prescribing Frequency
6 XHANCE Market Share & Prescribers by Prescribing Frequency The Market on this slide is defined as the sum of all intranasal steroid prescriptions written by physicians in the XHANCE target physician audience of approximately 21,000 physicians. Estimated based on monthly prescription data from thir
Slide 7: Q1 2022 Financial Update
Q1 2022 Financial Update
Slide 8: Financial Review – First Quarter
8 Financial Review – First Quarter 2021 XHANCE Net Revenue Increased 35% and Average Net Revenue per TRx Increased from $151 to $183 from Q1 2021 to Q1 2022 $11.0 $14.8 Q1 '21 Q1 '22 ($M) +35% $151 $183 Q1 '21 Q1 '22 +21% Net Revenue Average Net Revenue per TRx
Slide 9: Full Year 2022 Financial Guidance
9 Full Year 2022 Financial Guidance XHANCE Net Revenue ‒ Expected to be at least $90 million XHANCE Average Net Revenue per Prescription ‒ FY 2022 expected to exceed $220; previously expected to exceed $210 Operating Expense (GAAP) ‒ Expected to be between $135 – $140 million; approximately $1
Slide 10: Additional Phase 3b Clinical Trial Data Expected in Q2 22
10 Additional Phase 3b Clinical Trial Data Expected in Q2 2022 Recruitment Completed July 2021 Recruitment Completed October 2021 Top‐line results presented in Q1 2022 Top‐line results expected in June 2022
Slide 11: Closing Remarks
optinose_ ———— Closing Remarks
Slide 12: Key Takeaways and Q1 2022 Highlights
12 Key Takeaways and Q1 2022 Highlights Achieved Y/Y XHANCE Net Revenue Growth of 35% in Q1 2022 FY 2022 Revenue Guidance Implies Y/Y Growth of at least 22% Positive Top‐Line Results from ReOpen1 Reported in Q1 2022 +35% XHANCE Net Revenue Growth Q1 2022/Q1 2021 +21% XHANCE Net Revenue per TRx Growt
Slide 13: Investor Relations – Optinose Investor Contact
13 Investor Relations – NASDAQ: OPTN Optinose Investor Contact Jonathan Neely, VP, Investor Relations and Business Development 267‐521‐0531 Investors@optinose.com At 31 March 2022: – $91.4 million in cash – Long‐term debt: $130 million – 82.7 million common shares o/s – 15.7 million options, warrant
Slide 14: Building a Leading ENT / Allergy Specialty Company Corporate Presentation
Building a Leading ENT / Allergy Specialty Company Co r p o r a t e P r e s e n t a t i o n May 1 2 , 2 0 2 2